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Background: A substantial number of breast cancer patients are identified as being at high risk of developing
metastatic disease. With increasing number of targeted therapeutics entering clinical trials, chronic administration of
these agents may be a feasible approach for the prevention of metastases within this subgroup of patients. In this
preclinical study we examined whether Sunitinib, a multi-tyrosine kinase inhibitor which has anti-angiogenic and
anti-resorptive activity, is effective in the prevention of bone metastases.
Method: Sunitinib was administered daily with the first dose commencing prior to tumor cell inoculation.
Intracardiac injection was performed with MDA-MB23 bone-seeking cells, which were stably transfected with
DsRed2. In vivo plain radiography and fluorescent imaging (Berthold NightOwl) was used in the analysis of bone
metastases. Histomorphometry was used for the quantification of TRAP+ cells from bone sections and
immunohistochemistry was performed using an antibody reactive to CD34 for quantification of microvessel density.
Results: Preventive dosing administration of Sunitinib does not inhibit colonization of tumor cells to bone or
reduce the size of osteolytic lesions. There was a decrease in the number of TRAP+ cells with Sunitinib treatment
but this did not reach significance. Sunitinib inhibited tumor growth as determined by imaging of fluorescent
tumor area. Immunohistochemical analyses of microvessel density revealed a concomitant decrease in the number
of tumor blood vessels.
Conclusions: The findings suggest that Sunitinib can be used as a therapeutic agent for the treatment of bone
metastases but as a single agent it is not effective in terms of prevention. Therefore a combination approach with
other cytostatic drugs should be pursued.
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Up to 40% of patients with early stage breast cancer have
disseminated tumors cells in the bone marrow [1]. Fur-
thermore, bone is the most common site for breast
cancer metastasis with 50% of metastatic breast cancer
patients presenting with bone metastasis. Increased bone
resorption is becoming increasingly recognized as a risk
factor for development of metastatic tumor in the bone.* Correspondence: stiwari@email.uni-kiel.de
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reproduction in any medium, provided the orA number of preclinical studies have demonstrated that
heightened bone resorption creates an environment
that promotes growth of breast and prostate cancer
cells [2-7]. Therefore, agents that are anti-resorptive
may prevent the development of bone lesions and
reduce the risk of relapse in bone. Indeed, clinical trials
have shown that adjuvant anti-osteoclast therapy with
the bisphosphonates Zoledronic Acid results in decreased
numbers of disseminated tumor cells in the bone marrow
[8,9]. Furthermore, adjuvant Zoledronic Acid therapy in
post-menopausal women with early stage breast cancer
results in an increase in relapse free survival [10,11].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are effective in reducing tumor burden in bone [12-15].
The mode of action is through dual targeting of tumor
blood vessels and osteoclast activity [12,14,16-18]. Inhib-
ition of VEGF signaling can markedly affect bone
remodeling since VEGF directly affects the proliferation
and maturation of osteoclasts, osteoblasts, and their pre-
cursors [19-24]. However, their effectiveness in reducing
metastatic risk from disseminated tumor cells is un-
known. Amongst the patients who may benefit from
prophylactic treatment are those who have higher num-
bers of involved lymph nodes, larger tumor size, a triple
negative phenotype and/or those with a low estrogen,
high bone resorptive environment.
For a therapeutic approach in the prophylactic setting
to be rational, the angiogenic inhibitor should be cyto-
static since non-tumorigenic endothelial cells and osteo-
clasts are targeted. In addition, the toxicity profile should
be supportive of long-term chronic administration of the
drug. Sunitinib malate is a small tyrosine kinase inhibitor
with antiangiogenic activity and a safety profile which has
been reported to be acceptable for chronic outpatient ther-
apy [25]. The predetermined efficacious dose of 40 mg/kg
daily in mice maintains plasma Sunitinib concentration
above 50 ng/mL, selectively inhibiting VEGR2 and PDGF
receptor phosphorylation [26]. In clinical trials, dosing that
gives rise to Sunitinib plasma concentration of equal or
greater than 50 ng/mL was determined to be 50 mg/day
[27,28]. Recent phase III clinical trials have revealed that
administration of Sunitinib to patients with advanced
breast cancer did not increase progression free survival or
overall survival when used either as a single agent or in
combination with chemotherapeutic agents [29,30]. In this
study we tested the hypothesis that administration of a
clinically relevant dose of Sunitinib malate in the prophy-
lactic setting will decrease the number and extent of
osteolytic bone lesions. We show efficacy with Sunitinib
monotherapy in inhibiting tumor growth of bone metasta-
ses but not the number and size of osteolytic lesions.
Methods
Tumor cell inoculation
Bone-seeking MDA-MB231 cell line (MDA-231BO) was
obtained from Dr Toshiyuki Yoneda (University of
Texas Health Science Center). The cell line was stably
transfected with the fluorescent reporter gene DsRed2
(Clontech) and selected using 800 μg/ml of neomycin.
Following establishment of the stably transfected cell
line (MDA-231BO-DsRed2), three further in vivo pas-
sages to the bone were performed. One hundred thou-
sand MDA-231BO-DsRed2 cells were injected by
ultrasound guidance into the left cardiac ventricle of 6
week old female Fox nu/nu mice. Animal experiments
and care were in accordance with the guidelines ofinstitutional authorities and approved by local author-
ities (number, V 312–72241.121-10 (53-5/06).
Treatment groups
All treatment began two days prior to tumor cell inocu-
lation. One group of mice (n = 7) were treated with
40 mg/kg Sunitinib (orally/daily), a second group served
as a control group and was administered with carboxy-
methylcellulose vehicle formulation (orally/daily) (n = 7).
Fluorescent imaging
Anesthetized mice were imaged for DsRed2 fluores-
cence using a Peltier cooled charged-coupled device
camera (NightOWL LB 983; Berthold Technologies,
Bad Wildbad, Germany) to assess tumor growth at
weeks 3, 4 and 5 post-inoculation. The excitation source
is a ring light used for epi-illumination, mounted 12 cm
above the mice. Filters of 550 nm (±10 nm) and 605 nm
(±55 nm) were used to assess excitation and emission
signals respectively. The exposure time was set to 5 s.
Using the WinLight 32 software (Berthold), fluorescent
signals (expressed in counts/s) from the images were
calculated by selecting a rectangular region of interest
around the tumor and integrating the signal of each
pixel over the chosen area. To account for variations in
autofluorescence over time and between mice, the rect-
angular region of interest was placed over an adjacent
non-bone area to determine the background signal. This
signal was then subtracted from the tumor signal. The
tumor area was calculated using the Winlight32
software and expressed as mm2. The threshold of fluor-
escence emission was set to the level at which non-
specific fluorescent signal was no longer detected in
adjacent skin. This operated only on the periphery of
the tumor, after which an automated peak search func-
tion was utilized to delineate the area of the fluorescent
tumor.
Radiographs
Anesthetized mice were radiographed using a LoRad
Selenia digital mammography unit (Hologic GmbH,
Frankfurt/Main, Germany). Radiographs were taken at
weeks 3, 4 and 5 following intracardiac injection and
each radiograph was blindly evaluated by CS and A-CL.
The area of osteolytic lesions was measured using a
computerized image analysis system (IMPAX; AGFA,
Cologne, Germany) and results were expressed in square
millimeters.
Histomorphometry
Hind limbs from each animal were dissected and fixed
in neutral buffered formalin overnight at +4°C. The bone
samples were washed for two hours in cold PBS and
decalcified in acetic acid for 6 hours at +4°C. Following
Table 1 Total number of bone metastases in control and
Sunitinib groups






Control 7 14 21
Sunitinib (40 mg/kg/day) 7 12 21
Fluorescent bone metastatic lesions were counted at week 4 and week 5
following tumor cell inoculation. No significant differences in the mean
number of metastases was observed between groups.
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paraffin wax cut into 7 μM sections using a microtome.
Histomorphological analyses of the proximal tibia or the
distal femur were performed by cutting a series of 70 μm
sagittal sections every 200 μm, corresponding to the
upper, mid and lower regions and 3 sections were analysed
for each animal. The sections were then de-paraffinized
and stained with H&E, TRAP (tartrate-resistant acid
phosphatase), and CD34. TRAP staining was performed
according to van de Wijngaert and Burger [31] following
de-paraffinization and rehydration of the sections in serial
alcohol dilutions. Briefly, the sections were washed in
distilled water and incubated for 20 min in a solution con-
taining 0.2 M Sodium Acetate (Merck, Catalog Nr. 6268)
and 50 mM Tartaric Acid, pH 5.0 (Sigma-Aldrich, Catalog
Nr. T10-9). The sections were then incubated in the
TRAP running buffer containing 0.1mg/ml napthol AS-
MX phosphate (Sigma N4875) and 1.1 mg/ml Fast Red
TR (Sigma, F8764-16) for 1–3 h at 37°C until colour reac-
tion was complete. The sections were washed in distilled
water, stained with haematoxylin and mounted. TRAP
enumeration was performed by selecting the tumor region
in the distal femur or proximal tibia and counting the
number of TRAP-positive cells in contact with endosteal
surface. Five random regions were selected for counting
and data are expressed as the number of TRAP+ / bone
surface / mm2. CD34 staining was performed using the
Anti-Rat HRP-DAB staining kit (R&D Systems, Catalog
Nr. CTS017) with a rat monoclonal anti-CD34 antibody
(Gene Tex, Catalog Nr. GTX 28158) at 1:500 dilution
(50 μg/ml). Microvessel density (MVD) was evaluated by
calculating the selecting three highest areas of vascularity
across the tumor region and the number of angiogenic
vessels were counted in each field of view. The number of
vessels counted was divided by the field of view to yield
the MVD, expressed as MVD/mm2. Histomorphometric
measurement of tumor area was performed using the lon-
gitudinal section of the distal femur. Sections through the
tumor comprising of the largest tumor area were stained
with Goldners trichrome to identify tumor area and struc-
tural organization of the bone. Tumor area was measured
from the epiphyseal line of the growth plate and extending
into the diaphysis and bilaterally between the endocortical
surfaces. A line was drawn around the tumor margin using
Image J software and a scale bar was used to measure
lengths and calculate the cross-sectional area. At regions of
extensive cortical destruction, the tumor area included
growth to the boundary of the periosteum.
Statistical analyses
Two-tailed unpaired Student’s t tests were used to assess
differences between treated and control groups. P values
less than 0.05 were considered statistically significant.All statistical analyses were performed using GraphPad
Prism 4.03.Result
Preventive dosing administration of Sunitinib does not
inhibit colonization of tumor cells to bone
Intra cardiac injection of tumor cells recapitulates the
later stages of metastases whereby tumor cells that
metastasize to the skeleton adhere to the endosteal sur-
face and colonize bone. To determine if preventive Suni-
tinib treatment reduced establishment of colonized sites,
mice were administered with Sunitinib at the previously
established efficacious dose of 40 mg/kg/day. Dosing
commenced two days before the mice were inoculated
with tumor cells. Since tumor cells stably expressed the
red fluorescent protein DsRed2, the number of fluores-
cent spots corresponding to metastatic boney sites of
the mandible, hind legs, spine and ribs were counted.
Imaging at three weeks revealed no detectable bone
metastases but by four weeks a number of metastases
were visible. No significant difference in the number of
bone metastases was observed with Sunitinib treatment
compared to the control group (Table 1).Sunitinib does not reduce the size of osteolytic lesions
To determine if preventive treatment with Sunitinib
reduced the size of osteolytic lesions, plain radiography
imaging of leg and rib metastases was performed at week
5 following tumor cell inoculation and the size of the
osteolytic lesions was measured (Figure 1). Sunitinib treat-
ment did not significantly decrease the size of osteolytic
lesions compared to the control group.
To determine the effect of treatment on osteoclast
number, bone sections of the hind legs were stained for
TRAP to determine presence of osteoclasts at the
tumor-bone interface. Histological examination showed
lower TRAP-positive osteoclasts in the metastatic hind
legs of mice treated with Sunitinib but this difference
was not significant (Figure 2A). Histological appearances
of representative sections stained for TRAP are shown
in Figure 2B.
Figure 1 Size of osteolytic lesions (mm2) in nude mice with
bone metastases. Osteolytic lesions were analysed by plain
radiography 5 weeks following tumor cell inoculation; Control
(n = 7), Sunitinib (n = 7). Box plot shows 25–75 percentiles, whiskers
05–95 percentiles,+ indicates mean and line indicates median.
Significance was determined by 2-tailed Student t-test (*p < 0.05, op
< 0.1). No difference is observed in the size of osteolytic lesions with




Figure 2 (A) Number of TRAP-positive osteoclasts at the bone-tumor
formalin, decalcified in acetic acid and embedded in paraffin. Sections wer
tumor for each specimen were randomly selected and counted to determi
depicts mean ± SD of 5 animals per group. op < 0.1 (B) Representative sect
osteoclast and counterstained with Haematoxylin (blue) for detection of tu
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The effect of Sunitinib on tumor growth as a single
agent was evaluated. Fluorescent tumor area was deter-
mined as this parameter has been reported to have a
better correlation with micro-CT-based osteolytic lesion
grade than fluorescent intensity [32]. The fluorescent
area of metastatic tumors was measured when tumors
were first detected at 4 weeks following tumor cell
inoculation and again one week later. Mice treated with
Sunitinib alone had significantly lower tumor fluorescent
area at 4 weeks than mice in the control group (Figure 3,
Mean ± SD: 8.62 ± 5.13 vs 4.99 ± 3.00, p < 0.05). Further-
more, imaging at 5 weeks also revealed significantly
smaller tumors (Mean ± SD: 14.75 ± 4.97 vs 9.30 ± 5.42,
p < 0.05). Therefore Sunitinib preventive treatment
results in inhibition of growth of smaller tumors in bone
and is also effective in inhibiting tumor growth of estab-
lished tumors in the bone microenvironment. Histo-
logical measurement of cross-sectional tumor area from
the epiphyseal line of the distal femur and extending
into the diaphysis confirmed a decrease in size of tumor
in the bone with Sunitinib treatment (Figure 3B & C).
Furthermore, histological evaluation of tumor angiogen-
esis revealed that Sunitinib significantly inhibited tumor
neovascularization. The mean vessel density (MVD) ofSuntininb 
interface. Six weeks after tumor cell inoculation bones were fixed in
e stained for TRAP and counterstained for Haematoxylin. Five fields of
ne the number of TRAP-positive multinucleated cells. Column bar
ions of bone metastases stained for TRAP (Red) for detection of
mor cells. Magnification 20x.
AB Control Sunitinib C
Figure 3 (A) In vivo imaging of fluorescent tumor area to monitor tumor growth. Nude mice were injected with 1 x 105 MDA-231BO-
DsRed2 cells into the left ventricle and fluorescent imaging was performed at regular intervals. Analyses of fluorescent tumor area was performed
for Control (n = 7), Sunitinib (n = 7). Box plot shows 25–75 percentiles, whiskers 05–95 percentiles, + indicates mean and line indicates median.
Significance was determined by 2-tailed Student t-test (*p < 0.05). Growth inhibition with Sunitinib treatment is significantly reduced at 4 and 5
weeks following tumor cell inoculation (mean ± SD: Week 4. Ctrl 8.62 ± 5.13; Sunitinib 4.99 ±3.00. Week 5. Ctrl 14.75 ± 4.97; Sunitinib 9.30 ± 5.42).
(B) Histomorphometric determination of cross-sectional tumor size. Longitudinal sections of distal femur were stained with Goldners trichrome
and the tumor area measured from the epiphyseal line associated with the growth plate and extending into the diaphysis and bilaterally
between the endocortical envelope. The tumor margin measured is marked by a green line. At regions of extensive cortical destruction, the line
was drawn to the boundary of the periosteum. Representative sections of Goldner’s trichrome stained femur from control and Sunitinib treated
mice are shown. Magnification 5x (C) Cross-sectional tumor size in bone as measured by histomorphometry is significantly decreased with
Sunitinib treatment (Control mean ± SD 2.19 ± 0.39, n = 5; Sunitinib mean ± SD 1.59 ± 0.43; n = 5, p < 0.05).
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treatment compared to 139 ± 11 for control mice (p < 0.01,
Figure 4A). The data suggest that Sunitinib is effective in
inhibiting growth of bone metastases through inhibition of
new blood vessel formation. Histological appearances of
representative sections stained for CD34 are shown in
Figure 4B.
Discussion
In this study we evaluated whether preventive dose admin-
istration of the multi-tyrosine kinase Sunitinib is effective
in inhibiting bone metastases arising from disseminated
tumor cells. We show that Sunitinib used in the prophylac-
tic setting does not decrease the number of metastatic
colonized sites or inhibit subsequent progression of osteo-
lytic lesions. There is however a reduction in tumor growth
which is associated with a significant decrease in tumor
blood vessels. The findings suggest that Sunitinib alone is
not able to prevent colonization and expansion of dissemi-
nated tumor cells to bone but may be a useful adjunctive
therapy in reducing metastatic tumor burden.
It has been reported that prior administration of
Sunitinib at elevated doses (120 mg/kg/day) induce a"conditioning effect" which promote the formation of
metastasis by circulating tumor cells [33]. In this study
pre-treatment of mice with a dose of 40 mg/kg/day did
not lead to enhanced metastasis. This observation is
consistent with the findings of others that have used
lower therapeutically efficacious doses [34,35] and sup-
port a rationale for application of lower doses of Suniti-
nib to avoid augmented invasive or metastatic potential.
The concept of the vicious cycle of bone metastases
emphasizes the cross-talk between tumor cells and the
bone microenvironment in the process of tumor growth
and bone destruction [36,37]. Following colonization to
the bone, secretion of factors by tumor cells stimulate
osteoclastogenesis via upregulation of receptor activator
of nuclear factor kappa B ligand (RANKL) on osteoblast
and stromal cells. The increased bone resorptive activity
releases growth factors from the bone matrix which in
turn stimulate tumor cell growth giving rise to further
bone destruction. The observation that Sunitinib did not
show any therapeutic efficacy in inhibiting osteolytic
lesions despite a reduction in tumor size suggest that
osteoclast proliferation and activity was sufficiently
stimulated through secretions of growth factors by the
AControl SunitinibB
Figure 4 (A) Immunohistochemical staining of blood vessel density was performed on bone sections using the pan-endothelial marker
CD34 and quantified. Three regions with highest blood vessel density were selected and the number of angiogenic vessels counted. Box plot
shows 25–75 percentiles, whiskers 05–95 percentiles, line indicates median of 5 animals per group. Significance was determined by
2-tailed Student t-test (**p < 0.01). Blood vessel count is significantly reduced with Sunitinib treatment (mean ± SD: Ctrl 138.8 ± 27.3; Sunitinib 63.4
± 45.7). (B) Representative staining of CD34+ blood vessels (brown) and counterstained with Haematoxylin (blue). Magnification 200x.
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age and decreased vascularization was described previ-
ously for the treatment of bone metastases using the
histone deacetylase inhibitor Vorinostat [38]. The effect
was attributed to off-target effects of the drug on a
sub-population of resistant cells giving rise to increased
secretion of factors promoting osteolysis. Sunitinib has
recognized off-target activity with one report indicating
binding to at least 5 off-target kinases with high affinity
[39]. A possible off-target effect following Sunitinib ther-
apy is the tumor-independent increase in systemic levels
of factors such as granulocyte colony-stimulating factor
and osteopontin [40], factors which are known to promote
bone resorption [41-46]. In this regard, the application of
second-generation tyrosine kinase inhibitors (TKI's), such
as pazopanib and tivozanib, with improved potency and
selectivity may provide more effective treatment options
[47,48]. Another possibility which may explain our obser-
vation is the adaption of an evasive response by MDA-
MB231 cells. The cell line is of metastatic origin and anevasive response to disturbed tumor vasculature may be
manifested by increased secretion of certain factors which
induce osteolysis. Adaptive evasive responses leading to
increased invasiveness and distant metastases have been
observed in mouse models of pancreatic neuroendocrine
carcinoma and glioblastomas following antiangiogenic
targeting of VEGF signaling [49,50]. The mechanism
by which this occurs is not understood but the hypoxia/
HIF-1α pathway is implicated.
With an observed decrease in tumor growth in bone
there is a compelling biological rationale for the use of tar-
geted combination therapy with an anti-resorptive agent. A
retrospective study of patients with bone metastases from
renal cell carcinoma revealed an increase in progression
free survival and response rate in patients treated concomi-
tantly with bisphosphonate and Sunitinib [51]. Amongst
targeted agents which inhibit osteoclast activity and are
currently subject to clinical evaluation in breast cancer
bone metastases are inhibitors to mTOR, RANKL, Src and
Cathepsin K. A recent clinical trial administrating the
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inhibits mTORC1, showed beneficial effects on bone turn-
over and bone progression in postmenopausal women with
oestrogen-receptor-positive breast cancer [52]. Denosumab,
a human neutralizing antibody to RANKL, has been shown
to have a stronger inhibitory effect on bone resorption than
bisphosphonates [53-55]. Since long term Denosumab ther-
apy is generally well tolerated, introduction of Denosumab
as a second agent for the inhibition of osteoclast activity,
may further deprive tumor cells of growth factors seques-
tered in the bone matrix. In view of the fact that bone
remodeling is a complex process requiring orchestrated
differentiation of different cell types as well as angiogenesis,
establishment of treatment order of agents and dosage may
influence therapeutic effects of combination treatment [56].
Certain limitations of this study are outlined. One is
that only a single cell line was employed which is un-
likely to reflect the phenotypic properties of all dissem-
inating cells especially those disseminating from the
primary tumor at an early stage of the disease. Secondly,
the intracardiac injection model does not recapitulate
the requirement for cells to escape the primary site and
so not all the steps of the metastatic process can be
studied. Thirdly, the use of mouse models in itself has
the limitation that ethical time points arrive much earl-
ier than for example in a rat model and it is uncertain
whether a longer period of Sunitinib treatment may
eventually had an effect on osteolytic size.
With an increasing number of targeted therapies
entering clinical trials, there is an urgent need to apply
these drugs for the prevention of fully developed meta-
static lesions arising from disseminated tumor cells.
With advances in molecular biomarkers that refine and
improve risk stratification in patients, those with a high
risk of developing bone metastases may benefit from
adjuvant or prophylactic treatment with targeted thera-
peutics, as long as the cytotoxicity is supportive of long
term chronic administration. The targeted therapies that
may come into consideration are those that target genes
involved in disseminated tumor cells infiltration, survival
and colonization of the bone. In the event that metasta-
ses ensue, the drug can then be combined with a cyto-
toxic agent to invoke additive antitumor activity.
The data presented here establish that Sunitinib inhi-
bits tumor bone growth when applied in the preventive
setting. Further preclinical studies are warranted to test
the potential combination with an anti-resorptive agent
in the prophylactic setting, with the aim to improve their
overall antitumor efficacy. With the development of more
specific and well tolerated second generation TKIs which
inhibit VEGF signaling, the prospect of applying these
agents in combination with anti-resorptive agents holds
significant promise for the prevention of bone metastatic
disease.Conclusion
We present the first application of Sunitinib in a pre-
clinical mouse model for the prevention of bone metas-
tases and show efficacy in reducing tumor growth. We
advocate testing combination of targeted agents in a
therapeutic strategy that move to prevention to address
unmet clinical needs.
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